Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Status:
Completed
Trial end date:
2016-10-28
Target enrollment:
Participant gender:
Summary
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction
between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis
or trauma associated respiratory failure.
Primary Hypotheses:
- In CMV seropositive adults with severe sepsis or trauma , pulmonary and systemic CMV
reactivation amplifies and perpetuates both lung and systemic inflammation mediated through
specific cytokines, and contributes to pulmonary injury and multiorgan system failure,
AND
- Prevention of CMV reactivation with ganciclovir decreases pulmonary and systemic
inflammatory cytokines that are important in the pathogenesis of sepsis and trauma related
complications.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Genentech, Inc. National Heart, Lung, and Blood Institute (NHLBI)